WHO's in second? A practical review of world health organization group 2 pulmonary hypertension

Chest

Volumn 144, Issue 2, 2013, Pages 638-650

  Hansdottir, Sif ^a   Groskreutz, Dayna J ^a   Gehlbach, Brian K ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RIOCIGUAT; SILDENAFIL;

AGING; AORTA VALVE DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG SAFETY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; LEFT VENTRICULAR ASSIST DEVICE; LIVER FUNCTION TEST; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MITRAL VALVE DISEASE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTIVE CARDIOMYOPATHY; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; WORLD HEALTH ORGANIZATION;

EID: 84881540403     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2114     Document Type: Article

References (103)

1. Oudiz RJ. Pulmonary hypertension associated with leftsided heart disease. Clin Chest Med. 2007; 28 (1): 233-241.
2. Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012; 98 (24): 1805-1811.
3. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S55-S66.
4. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34 (4): 888-894.
5. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult-a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012; 31 (9): 913-933.
6. Fishman AP. Clinical classifi cation of pulmonary hypertension. Clin Chest Med. 2001; 22 (3): 385-391.
7. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classifi cation of pulmonary hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S43-S54.
8. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53 (17): 1573-1619.
9. Galiè N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30 (20): 2493-2537.
10. Galiè N, Hoeper MM, Humbert M, et al; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009; 34 (6): 1219-1263.
11. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142 (2): 448-456.
12. Chatterjee NA, Lewis GD. What is the prognostic significance of pulmonary hypertension in heart failure? Circ Heart Fail. 2011; 4 (5): 541-545.
13. Ben-Dor I, Goldstein SA, Pichard AD, et al. Clinical profi le, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. Am J Cardiol. 2011; 107 (7): 1046-1051.
14. Alexopoulos D, Lazzam C, Borrico S, Fiedler L, Ambrose JA. Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension. J Am Coll Cardiol. 1989; 14 (2): 319-322.
15. Braunwald E, Braunwald NS, Ross J Jr, Morrow AG. Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med. 1965; 273: 509-514.
16. Semler HJ, Shepherd JT, Wood EH. The role of vessel tone in maintaining pulmonary vascular resistance in patients with mitral stenosis. Circulation. 1959; 19 (3): 386-394.
17. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S85-S96.
18. Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail. 2009; 2 (2): 105-112.
19. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J. 2003; 24 (4): 320-328.
20. Delgado JF, Conde E, Sánchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005; 7 (6): 1011-1016.
21. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000; 102 (14): 1718-1723.
22. Snopek G, Pogorzelska H, Rywik TM, Browarek A, Janas J, Korewicki J. Usefulness of endothelin-1 concentration in capillary blood in patients with mitral stenosis as a predictor of regression of pulmonary hypertension after mitral valve replacement or valvuloplasty. Am J Cardiol. 2002; 90 (2): 188-189.
23. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012; 59 (5): 442-451.
24. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation. 2012; 126 (8): 975-990.
25. West JB, Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation. 1995; 92(3): 622-631.
26. Tsukimoto K, Mathieu-Costello O, Prediletto R, Elliott AR, West JB. Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol. 1991; 71(2): 573-582.
27. Kay JM, Edwards FR. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol. 1973; 111 (4): 239-245.
28. Lee YS. Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema. Jpn Circ J. 1979; 43 (10): 945-954.
29. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail. 2008; 14 (8): 695-702.
30. Parker F, Weiss S. The nature and signifi cance of the structural changes in the lungs in mitral stenosis. Am J Pathol. 1936 ;12(5):573-598.
31. Melenovsky V, Al-Hiti H, Kazdova L, et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafi l. J Am Coll Cardiol. 2009; 54 (7): 595-600.
32. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005; 11 (1): 12-20.
33. Ferguson JJ. Meeting highlights: highlights of the 51st annual scientifi c sessions of the American College of Cardiology. Atlanta, Georgia, USA. March 17-20, 2002. Circulation. 2002; 106 (7): E24-E30.
34. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multicenter randomized study. Cardiology. 2008; 109 (4): 273-280.
35. Hassoun PM, Mouthon L, Barberà JA, et al. Infl ammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009; 54 (suppl 1): S10-S19.
36. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119 (3): e21-e181.
37. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001; 37 (1): 183-188.
38. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010; 106 (2): 284-286.
39. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009; 53 (13): 1119-1126.
40. Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007; 99 (8): 1146-1150.
41. Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail. 2011; 4 (5): 644-650.
42. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol. 2010; 55 (16): 1701-1710.
43. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010; 3 (5): 588-595.
44. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest. 2007; 131(1): 94-100.
45. Robbins IM, Newman JH, Johnson RF, et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009; 136 (1): 31-36.
46. Willens HJ, Kessler KM. Severe pulmonary hypertension associated with diastolic left ventricular dysfunction. Chest. 1993; 103 (6): 1877-1883.
47. Rajagopalan N, Garcia MJ, Rodriguez L, et al. Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol. 2001; 87 (1): 86-94.
48. Choi EY, Ha JW, Kim JM, et al. Incremental value of combining systolic mitral annular velocity and time difference between mitral infl ow and diastolic mitral annular velocity to early diastolic annular velocity for differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Soc Echocardiogr. 2007; 20 (6): 738-743.
49. Fenton MJ, Chubb H, McMahon AM, Rees P, Elliott MJ, Burch M. Heart and heart-lung transplantation for idiopathic restrictive cardiomyopathy in children. Heart. 2006; 92 (1): 85-89.
50. Cam A, Goel SS, Agarwal S, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis. J Thorac Cardiovasc Surg. 2011; 142 (4): 800-808.
51. Malouf JF, Enriquez-Sarano M, Pellikka PA, et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profi le and prognostic implications. J Am Coll Cardiol. 2002; 40 (4): 789-795.
52. Bonow RO, Carabello BA, Chatterjee K, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of patients With Valvular Heart Disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 52 (13): e1-e142.
53. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ Jr. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg. 2011; 141 (6): 1424-1430.
54. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol. 2010; 55 (11): 1080-1090.
55. Naidoo DP, Mitha AS, Vythilingum S, Chetty S. Pulmonary hypertension in aortic regurgitation: early surgical outcome. Q J Med. 1991; 80 (291): 589-595.
56. Zener JC, Hancock EW, Shumway NE, Harrison DC. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol. 1972; 30 (8): 820-826.
57. Goodale F Jr, Sanchez G, Friedlich AL, Scannell JG, Myers GS. Correlation of pulmonary arteriolar resistance with pulmonary vascular changes in patients with mitral stenosis before and after valvulotomy. N Engl J Med. 1955; 252 (23): 979-983.
58. Vincens JJ, Temizer D, Post JR, Edmunds LH Jr, Herrmann HC. Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension. Circulation. 1995; 92 (suppl 9): II137-II142.
59. Fawzy ME, Hassan W, Stefadouros M, Moursi M, El Shaer F, Chaudhary MA. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis. 2004; 13 (6): 942-947., discussion 947-948.
60. Bonow RO, Carabello BA, Chatterjee K, et al; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118(15): e523-e661.
61. Elliott CG, Palevsky HI. Treatment with epoprostenol of pulmonary arterial hypertension following mitral valve replacement for mitral stenosis. Thorax. 2004; 59 (6): 536-537.
62. Bomma C, Ventura HO, Daniel G, Patel H. Adjunctive sildenafi l for the treatment of pulmonary hypertension after mitral valve replacement. Congest Heart Fail. 2006; 12 (6): 347-348.
63. Gan CT, Lankhaar JW, Marcus JT, et al. Impaired left ventricular fi lling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2006; 290 (4): H1528-H1533.
64. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997; 134 (1): 44-54.
65. Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction/clinical perspective. Circ Heart Fail. 2011 ;4(3):257-265.
66. Fleg JL, O'Connor F, Gerstenblith G, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol. 1995; 78 (3): 890-900.
67. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987; 107 (2): 216-223.
68. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest. 2002; 121 (2): 513-518.
69. McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008; 10 (2): 149-156.
70. Lupi E, Dumont C, Tejada VM, Horwitz S, Galland F. A radiologic index of pulmonary arterial hypertension. Chest. 1975; 68 (1): 28-31.
71. Milne EN. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. Radiographics. 2012; 32 (4): 1085-1087.
72. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002; 39 (7): 1214-1219.
73. Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr. 1999; 12 (8): 655-662.
74. Opotowsky AR, Ojeda J, Rogers F, et al. A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc Imaging. 2012 ;5(6):765-775.
75. Zile MR, Gottdiener JS, Hetzel SJ, et al; I-PRESERVE Investigators. Prevalence and signifi cance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011; 124(23): 2491-2501.
76. Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. J Am Soc Echocardiogr. 2008; 21 (6): 715-719.
77. Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. Chest. 2007; 131 (2): 395-401.
78. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of fi lling pressures. J Am Coll Cardiol. 1997; 30 (6): 1527-1533.
79. Guazzi M, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol. 2005; 46 (10): 1883-1890.
80. Paolillo S, Farina S, Bussotti M, et al. Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. Eur J Prev Cardiol. 2012; 19 (5): 960-971.
81. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010; 56 (11): 845-854.
82. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol. 2010; 56 (11): 855-863.
83. Paulus WJ. Culprit mechanism(s) for exercise intolerance in heart failure with normal ejection fraction. J Am Coll Cardiol. 2010; 56 (11): 864-866.
84. Grewal J, McCully RB, Kane GC, Lam C, Pellikka PA. Left ventricular function and exercise capacity. JAMA. 2009; 301 (3): 286-294.
85. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991; 17 (5): 1065-1072.
86. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005; 127 (5): 1637-1646.
87. Hemnes AR, Pugh ME, Newman AL, et al. End tidal CO(2) tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. Chest. 2011; 140 (5): 1267-1273.
88. Fox BD, Shimony A, Langleben D, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension [published online ahead of print Dec 20, 2012]. Eur Respir J. doi:10.1183/09031936
89. Halpern SD, Taichman DB. Misclassifi cation of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009; 136 (1): 37-43.
90. Ryan JJ, Rich JD, Thiruvoipati T, Swamy R, Kim GH, Rich S. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classifi cation of patients with pulmonary hypertension. Am Heart J. 2012; 163 (4): 589-594.
91. Pichard AD, Kay R, Smith H, Rentrop P, Holt J, Gorlin R. Large V waves in the pulmonary wedge pressure tracing in the absence of mitral regurgitation. Am J Cardiol. 1982; 50 (5): 1044-1050.
92. Costard-Jäckle A, Fowler MB. Infl uence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defi ning a high risk group. J Am Coll Cardiol. 1992; 19 (1): 48-54.
93. Chen JM, Levin HR, Michler RE, Prusmack CJ, Rose EA, Aaronson KD. Reevaluating the signifi cance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantifi cation of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 1997; 114 (4): 627-634.
94. Lindenfeld J, Albert NM, Boehmer JP, et al; Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010; 16 (6): e1-e194.
95. Lewis GD, Shah R, Shahzad K, et al. Sildenafi l improves exercise capacity and quality of life in patients with systolicheart failure and secondary pulmonary hypertension. Circulation. 2007; 116 (14): 1555-1562.
96. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafi l in the therapeutic management of heart failure. J Am Coll Cardiol. 2007; 50 (22): 2136-2144.
97. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124 (2): 164-174.
98. Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg. 2007; 83 (5): 1697-1705.
99. Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J Heart Lung Transplant. 2010; 29(2): 201-208.
100. Pauwaa S, Bhat G, Tatooles AJ, et al. How effective are continuous fl ow left ventricular assist devices in lowering high pulmonary artery pressures in heart transplant candidates? Cardiol J. 2012; 19 (2): 153-158.
101. Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fi xed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg. 2007; 31 (4): 698-702.
102. Torre-Amione G, Southard RE, Loebe MM, et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. J Heart Lung Transplant. 2010; 29 (2): 195-200.
103. Alba AC, Rao V, Ross HJ, et al. Impact of fi xed pulmonary hypertension on post-heart transplant outcomes in bridgeto-transplant patients. J Heart Lung Transplant. 2010; 29 (11): 1253-1258.